Stemgent Starts Scottish Protein Tools Venture

Mar 03, 2010

NEW YORK (GenomeWeb News) – Stem cell products developer Stemgent said today that it has started a new business in Scotland that will develop reagents and kits and offer services for use in studying the ubiquitin proteasome pathway (UPP) for drug research.

Stemgent, which has operations in Boston and San Diego, will invest roughly $4.5 million over three years in the new venture, which is based in Dundee.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

The Scan

Silencing for Preeclampsia

A new study finds that a placental protein linked with preeclampsia can be targeted by RNA silencing, according to the New Scientist.

Settlement Expected in Duke Case

A settlement is expected in a Duke University lawsuit hinging on using falsified data to win grants, Retraction Watch and Science report.

This Week in PNAS

In PNAS this week: approach for analyzing the expression of endogenous retroviruses, circular RNAs that influence host-virus interactions, and more.

Something Different

A phylogenetic analysis finds that the rare hemimastigotes form their own supra-kingdom, CBC reports.

Featured White Papers

xMAP Cookbook: A collection of methods and protocols for developing multiplex assays with xMAP Technology

Stroma Liquid Biopsy - Biomarkers of the Dysregulation of the Serum Proteome in Cancer

Cleanascite Lipid Removal & Clarification Reference Applications

Albumin Removal Reference Applications

Dec

03

Featured Webinar

Application of a Novel ISH Approach to Elucidate Splice Variants in Schizophrenia

This webinar will demonstrate how a research team at the National Institutes of Health evaluated a novel in situ hybridization approach and applied it to study splice variants related to schizophrenia.

Main menu